Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (Pre-Sequencing, Sequencing, Data Analysis), By Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing Centrifuges), By Application (Screening, Companion Diagnostics, Other Diagnostics), By End-Use (Hospitals, Clinics, Laboratories) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Clinical Oncology Next Generation Sequencing Market Size

The global clinical oncology next generation sequencing (NGS) market size was valued at USD 567.50 million in 2024 and is projected to grow from USD 666.25 million in 2025 to reach USD 1,506.37 million by 2033, growing at a CAGR of 10.74% during the forecast period (2025–2033).

Clinical Oncology Next Generation Sequencing (NGS) refers to a set of advanced genomic technologies used to analyze the genetic makeup of cancer cells. NGS enables the rapid sequencing of DNA or RNA to identify genetic mutations, alterations, and variations that may drive cancer development. This technology allows for a comprehensive analysis of a tumor's genetic profile, providing critical insights into the underlying causes of cancer and its behavior.

By using NGS, clinicians can detect rare and novel mutations that are often missed by traditional methods. This information can guide personalized treatment plans tailored to the individual’s unique genetic makeup, improving the effectiveness of therapies. NGS is also used for cancer diagnosis, prognosis, and monitoring, offering the potential for earlier detection and more targeted, less invasive treatments.

As a result, NGS plays a crucial role in advancing precision medicine in oncology, making it a key tool in the fight against cancer.

Clinical Oncology Next Generation Sequencing Market Trends

Integration of liquid biopsy with NGS and artificial intelligence

Liquid biopsy allows for the detection of malignant tumors by identifying circulating tumor cells (CTCs) and circulating tumor DNA (ct-DNA) in the bloodstream. When coupled with NGS, this approach enhances the ability to sequence and analyze the genetic material, providing a deeper molecular profile of the cancer. This improves the accuracy and speed of cancer diagnosis, making it possible to detect mutations that might otherwise go unnoticed.

• A key example of this innovation was highlighted in a June 2024 study published in Nature Medicine, where an AI platform was trained to recognize ct-DNA by analyzing DNA sequencing data obtained from blood samples through liquid biopsy.

This combination of liquid biopsy, NGS, and AI not only improves the precision of ct-DNA detection but also makes cancer monitoring more non-invasive and efficient.

Strategic partnerships enhancing accessibility of NGS-based testing

Strategic partnerships are also contributing to the accessibility and growth of NGS-based testing. As more collaborations emerge in the oncology space, NGS testing becomes increasingly available to a broader patient population. These partnerships are instrumental in enhancing precision oncology, improving patient outcomes, and accelerating the implementation of genomic testing.

• For instance, in May 2023, Pfizer and Thermo Fisher Scientific Inc. entered into a cooperative agreement to improve local access to NGS-based testing for breast and lung cancer patients. This collaboration aims to speed up gene analysis, allowing medical professionals to offer personalized treatments quickly.

By advancing the adoption of NGS in clinical oncology, such partnerships are fueling market growth and supporting the demand for more individualized and accurate cancer therapies.

Clinical Oncology Next Generation Sequencing Market Growth Drivers

Advancement in NGS technologies

Recent advancements in Next-Generation Sequencing (NGS) technologies have significantly improved the ability to sequence cancer-related genes in clinical practice. As NGS technologies evolve, their role in personalized and targeted cancer treatments becomes more critical, leading to a broader adoption across various cancer subtypes.

• For example, in December 2022, Med Genome Inc. introduced the TruSight Oncology 500 (TSO-500), a comprehensive NGS assay designed for tumor profiling. This assay can detect key genomic variants and immunotherapy biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI), making it a valuable tool for advancing cancer research and precision medicine.

These advancements enhance the effectiveness of tailored cancer treatments, meeting the growing demand for personalized therapies across multiple cancer types.

Expanding applications of NGS technology in disease modeling

The growing use of Next-Generation Sequencing (NGS) technologies is transforming the landscape of cancer diagnosis and treatment. These advanced tools enable precise, high-throughput genomic analysis, allowing for deeper insights into the genetic makeup of tumors. As a result, NGS is increasingly being integrated into clinical laboratories and is expected to play a pivotal role in advancing cancer genomic research and personalized medicine.

• For example, Illumina Inc.’s Nova-seq platform offers faster and more accurate sequencing, significantly enhancing the analysis of various cancer genomes. This technology is revolutionizing how cancer mutations and genomic variations are identified, enabling more targeted and effective treatments.

The widespread adoption of such NGS technologies is driving more accurate cancer genomic analysis, accelerating the shift toward precision oncology. As these innovations continue to evolve, they are fueling market growth by improving cancer diagnosis, optimizing treatment strategies, and enhancing personalized care for patients worldwide.

Market Restraint

Ethical and privacy concerns

The rapid adoption of Next-Generation Sequencing (NGS) technology in clinical oncology raises significant ethical and privacy concerns, particularly regarding the protection of sensitive genetic data. NGS can generate vast amounts of personal genetic information, making it a potential target for data breaches.

• A notable example occurred in 2023 when Illumina Inc., a leading NGS technology provider, experienced a security breach that exposed the genetic information of cancer patients, highlighting the risks associated with genetic data privacy and security.

Such incidents undermine confidence in genomic analysis and NGS-driven cancer treatments, potentially hindering market growth.

Market Opportunities

Rising adoption of pan-cancer genomic profiling tests

An emerging opportunity in the clinical oncology NGS market lies in the growing adoption of pan-cancer genomic profiling tests. These tests allow for the comprehensive analysis of multiple cancer types with a single diagnostic procedure, significantly enhancing the efficiency and accuracy of cancer detection.

• For instance, Foundation Medicine’s FoundationOne Liquid CDx utilizes blood samples and NGS to identify genetic mutations in circulating cell-free DNA from over 300 cancer-related genes. This approach offers a more streamlined and less invasive method for analyzing a broad range of cancers.

As the demand for pan-cancer genomic profiling increases, the adoption of NGS technologies accelerates, creating substantial opportunities for companies that offer advanced diagnostic solutions.

Regional Insights

North America: Dominant region with 48.68% market share

North America remains the dominant market for clinical oncology NGS market due to its advanced healthcare infrastructure, and the presence of key market players. The U.S., in particular, drives demand with its focus on genomic medicine and precision diagnostics. The region's strong regulatory support and increasing investments in molecular diagnostics and personalized medicine further fuel market growth. Moreover, innovations and new product launches by companies like Thermo Fisher Scientific and Illumina, Inc. continue to solidify their leadership in North America. 

Asia-Pacific: Fastest growing region with highest market CAGR

Asia-Pacific is experiencing rapid growth in clinical oncology (NGS), driven by increasing investments in healthcare infrastructure, expanding biotechnology sectors, and a rising demand for genomic research and diagnostics. Countries like China, India, and Japan are witnessing a surge in research activities, particularly in oncology, leading to a higher demand for clinical oncology NGS technology.

Country Insights

• U.S.- The U.S. remains a market leader in clinical oncology NGS, driven by its advanced healthcare system, focus on precision medicine, and ongoing research in cancer treatment technologies. In June 2023, PreCheck Health Services Inc. launched a comprehensive cancer panel utilizing NGS to detect gene-level alterations, improving personalized treatment regimens. This innovation reflects the country's commitment to advancing cancer care through cutting-edge technology and precision therapies.
• Canada– Canada’s clinical oncology NGS market is rapidly growing, with a strong focus on improving healthcare access and supporting individualized treatments. The McGill University Health Centre (MUHC) has incorporated NGS into clinical trials, analyzing breast, colorectal, and ovarian cancers to determine targeted therapies based on genomic alterations. This approach highlights Canada's increasing adoption of NGS to offer personalized cancer care and enhance treatment efficacy.
• UK - The UK market for clinical oncology NGS is expanding, supported by government-backed initiatives, universal healthcare access, and a growing focus on precision medicine. The NHS Genomic Medicine Service uses NGS to profile cancer and guide personalized treatments, ensuring the delivery of targeted care to patients. This commitment to genomics-driven oncology reflects the UK’s dedication to enhancing cancer treatment and outcomes through advanced technologies.
• Germany - Germany’s healthcare system prioritizes the diagnosis and treatment of diseases, including cancer, with an increasing adoption of NGS in clinical oncology. The German Cancer Consortium (DKTK) collaborates with multiple institutions to integrate NGS into cancer research, especially in gene editing and immunotherapy. This collaboration strengthens Germany’s position as a leader in cancer genomics, promoting innovative treatment solutions and advancing precision oncology.
• India- India's clinical oncology NGS market is expanding rapidly, driven by public and private sector efforts in genomic research and cancer diagnostics. In May 2024, MapmyGenome launched an initiative offering NGS-based cancer testing, particularly targeting rural populations through mobile clinics and government partnerships. This initiative represents India’s efforts to enhance cancer care accessibility and deliver personalized treatments across diverse communities.
• Japan - Japan plays a key role in the clinical oncology NGS market, benefiting from a strong healthcare system and a culture of technological innovation. Many Japanese hospitals have adopted NGS-based mutational profiling to improve cancer diagnosis and therapy, particularly for clinical trials. This progressive approach positions Japan as a leader in incorporating advanced genomic technologies into oncology care, further enhancing patient outcomes.

Segmentation Analysis

The global clinical oncology next generation sequencing (NGS) market is segmented into application, technology, workflow, and end-user.

By Application

Companion diagnostic segment dominates the market with the highest market revenue

The companion diagnostics segment leads the market, driven by its crucial role in matching patients with targeted therapies based on their genetic profiles. By identifying specific biomarkers, companion diagnostics enhance the effectiveness of personalized treatments. For example, in August 2024, the FDA approved Illumina's cancer biomarker test alongside two companion diagnostics, enabling quick patient matching to tailored therapies. This growth reflects the increasing demand for precise, personalized cancer treatments, making companion diagnostics integral to clinical oncology.

By Technology

Target sequencing and re-sequencing segment dominates the market with the highest market revenue

The target sequencing and re-sequencing segment dominates the market due to its cost efficiency, specificity, and superior coverage. This technology enables oncologists to analyze targeted genetic mutations with high precision, improving treatment decisions. For instance, Foundation Medicine's FoundationOne CDx uses targeted sequencing on tissue biopsy samples to identify gene alterations and fusions, crucial for personalized cancer therapy. The segment's dominance reflects its impact on cancer genomics, driving better diagnostic accuracy and treatment planning.

By Workflow

NGS Data Analysis segment dominates the market with the highest market revenue

The NGS data analysis segment holds the largest market share, transforming raw sequencing data into actionable insights that drive cancer diagnosis. Accurate data analysis is critical in interpreting complex genetic information and guiding treatment decisions. For instance, ArrayGen Technologies Pvt. Ltd. offers advanced NGS analysis services, evaluating large-scale omics datasets to uncover genetic mutations. This segment's growth highlights the increasing reliance on data analysis in clinical oncology to enable informed, precise cancer treatment strategies.

By End-User

Diagnostic laboratories segment dominates the market with the highest market revenue 

Diagnostic laboratories dominate the clinical oncology NGS market due to their pivotal role in genetic testing and cancer diagnostics. As the demand for specialized cancer diagnostics grows, laboratories are essential for analyzing genetic profiles to inform treatment decisions. For example, Mayo Clinic Laboratories offers a targeted lung cancer panel that checks for mutations and gene rearrangements, illustrating the increasing importance of precision diagnostics. This segment’s growth is driven by the need for accurate, personalized cancer care and effective treatment planning.

Company Market Share

Key players in the clinical oncology NGS market are investing in innovative technologies, R&D, and personalized medicine to improve cancer diagnoses, therapy, and monitoring, ensuring competitive growth in the evolving clinical oncology NGS market landscape.

Guardant Health: An emerging player in the Global Clinical Oncology Next Generation Sequencing (NGS) Market

Guardant Health is a market leader in precision oncology and liquid biopsy, leveraging Next-Generation Sequencing (NGS) technology to analyze circulating tumor DNA (ct-DNA). This non-invasive approach allows for the early detection of cancer and the monitoring of treatment responses, providing valuable insights into tumor mutations and genetic alterations.

Recent developments at Guardant Health include

• In July 2024, Guardant Health improved its Guardant360 liquid covering 739 genes. This makes it possible to detect biomarkers in advanced solid tumors with greater precision. The test provides ten times higher sensitivity for tumor burden measurement.

Recent Developments

• May 2024 – G-know Me, a Bengaluru-based informatics start-up, partnered with researchers from Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge in the United Kingdom to develop an automated workflow platform for interpreting whole genomic sequence data in cancer. This collaboration aims to enhance the accuracy and efficiency of genomic data analysis, facilitating more precise and personalized cancer treatments.
• November 2024 – Tempus, a healthcare technology company specializing in precision medicine through AI, conducted a retrospective analysis of over 5,500 patients with advanced non-small cell lung cancer (NSCLC). The study found that combining RNA- and DNA-based next-generation sequencing (NGS) identified significantly more actionable structural variations than DNA sequencing alone.

Analyst Opinion

As per our analyst, the global clinical oncology next generation sequencing (NGS) industry is experiencing robust growth, driven by the rising demand for personalized cancer diagnosis and treatment. NGS technology has become a critical tool for identifying specific genetic abnormalities and biomarkers that enable targeted therapies, helping oncologists customize treatment plans based on a patient's unique genetic makeup.

Moreover, the global rise in cancer incidence, combined with ongoing advancements in NGS technology and continuous funding in research and development, has significantly enhanced the precision and effectiveness of cancer therapies. Despite these advancements, challenges such as data privacy concerns, the complexity of interpreting vast genomic data, and the high cost of NGS-based testing remain.

However, the industry is addressing these issues through strategic collaborations, innovations in data analysis tools, and the integration of artificial intelligence (AI) to streamline genomic data interpretation. Moreover, increased regulatory support and initiatives to make NGS testing more affordable are helping to overcome barriers to widespread adoption, ensuring that more patients benefit from these groundbreaking, individualized treatments.